F. Cardenal

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

Reginald V. Lord, Jan Brabender, David R. Gandara et al. · PubMed · 2002 · 671 citations

Medicine, Molecular Biology, Oncology +14

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients

H. Cortés-Funes, Carlos Gegúndez Gómez, Rafael Rosell et al. · Annals of Oncology · 2005 · 231 citations · Full text

Medicine, Oncology, Pharmacology +11

Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial

V. Alberola, Carlos Camps, Mariano Provencio et al. · Journal of Clinical Oncology · 2003 · 193 citations

Medicine, Oncology, Pharmacology +14

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

R. Rosell, R. Gervais, A. Vergnenègre et al. · Journal of Clinical Oncology · 2011 · 148 citations

Medicine, Oncology, Pharmacology +16

High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC

Daniel D. Karp, Luis Paz‐Ares, S. Novello et al. · Journal of Clinical Oncology · 2008 · 49 citations

Medicine, Oncology, Pharmacology +15